Accordingly, a recent promising work on a mouse model of breast cancer has shown that systemic treatment with an ezrin inhibitor reduces the migration of cancer cells, also diminishing the metastatic burden to the axillary lymph nodes and the lungs [22]. This evidence concerns the gene EZR and breast cancer.